AURKA_207-215–specific TCR-transduced CD8⁺ T cells mediate antileukemia reactivity in vivo. (A) Winn assay: tumor suppression curve. NOG mice were coinjected with GANMO-1 cells (5 × 10⁶) and either 2.5 × 10⁷ AURKA_207-215–specific TCR gene-modified (AURKA-TCR) or non–gene-modified (NGM) CD8⁺ T cells (n = 4 group). Subsequently, 5 weekly infusions of the respective CD8⁺ T-cell populations (5 × 10⁶ cells per infusion) were administered intravenously. Tumor growth was monitored every 5 days. (B) Winn assay: survival curve. Treatment with AURKA_207-215–specific TCR gene-modified (AURKA-TCR) CD8⁺ T cells significantly prolonged survival (P < .005). (C) Therapeutic adoptive transfer model. NOG mice (n = 4 per group) were inoculated with 5 × 10⁶ of GANMO-1 cells. Intravenous administration of either 5 × 10⁶ AURKA_207-215–specific TCR gene-modified (AURKA-TCR) or non–gene-modified (NGM) CD8⁺ T cells commenced on the same day and was continued weekly thereafter. Therapeutic infusions of AURKA_207-215–specific TCR gene-modified CD8⁺ T cells significantly suppressed tumor growth (P < .02). Error bars represent SDs.